gynecologic cancer
Conditions
Interventions
Aprepitant 125mg PO on day 1 Aprepitant 80mg PO on days 2 to 3 Granisetron 3mg IV on day 1 Dexamethasone 16mg or 8mg IV on day 1 Dexamethasone 4mg PO on days 2 to 3
Granisetron 3mg IV on day 1 De
Sponsors
Department of gynecology, Fukuoka University Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Patient is 20 years and over 2) Gynecologic cancer patients who are scheduled to receive their first course of TC regimen (Carboplatin/Paclitaxel) chemotherapy
Exclusion criteria
Exclusion criteria: 1) Patient has a serious hepatic insufficiency or renal failure 2) Patient has nausea or vomiting within 24 hours prior to chemotherapy 3) Patient has been treated with antiemetic agents within 48 hours prior to chemotherapy 4) Patient has any illness (e.g. central nervous system tumors, gastrointestinal obstruction, active peptic ulcer, brain metastasis) caused nausea or vomiting except for chemotherapy-induced nausea and vomiting 5) Patient is unable to be administered dexamethasone for 3 days due to associated illnesses such as out-of-control diabetes mellitus 6) Patient is receiving pimozide 7) Patient is judged inappropriate by the investigator as subject for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients with Complete Response (no vomiting and no use of rescue therapy) during overall phase (5 days following initiation of chemotherapy) in first cycle. | — |
Countries
Japan
Outcome results
None listed